Page 85 - Read Online
P. 85

Page 14 of 26     Skorupan et al. J Cancer Metastasis Treat 2023;9:5  https://dx.doi.org/10.20517/2394-4722.2022.106

                                  [143]
               in females with PACC . Retrospective population-based studies suggest that 32%-54% of patients present
               with distant metastatic disease [142-145] . The most frequent site of metastasis is the liver. While this proportion
               is similar (in some studies) to that for PDAC, PACC patients have improved median survival compared to
                                       [145]
               PDAC at every disease stage . This is particularly notable in patients with PACC who undergo resection,
               where median OS can exceed 70 months, but rarely reaches 36 months in PDAC patients. PACC tumors are
               typically larger at diagnosis than those seen in PDAC. Interestingly, primary tumor size did not correlate
               with the time to onset of metastatic disease or with the presence of metastatic lesions . Those with mixed
                                                                                       [141]
               acinar-neuroendocrine and acinar-ductal pathologies appear to have similar prognosis and tumor
               characteristics . PACC  is  still  an  aggressive  tumor,  but  prognosis  is  superior  to  PDAC.  PACC
                           [146]
               retrospective case series examining clinical outcomes are summarized in Table 5 [142-148] .


               PACC has been seen in kindreds with familial adenomatous polyposis , Lynch syndrome , and BRCA
                                                                            [149]
                                                                                             [150]
               mutation [134,151] , but it is difficult to determine how influential these genetic syndromes are in this disease
               given the small number of cases overall. Specific clinical or environmental risk factors for PACC remain
               unknown.

               PACC diagnosis and imaging
               Diagnosis of PACC is by pathology. Tumor samples can be obtained through surgical resection or needle
               aspiration. Diagnosing PACC from a fine needle aspiration can present a challenge as cytologic samples can
               be easily confused with normal acinar cells or sampling from a neuroendocrine tumor. Labate et al. were the
               first to describe the cytopathology of PACC in detail and were able to correctly diagnose PACC from a
               cytology specimen in just 2 of 7 cases . Subsequently, the diagnostic yield has not appeared to improve, as
                                              [152]
               only 2 of 7 cases reported since could be definitively diagnosed as PACC based on cytology alone [153-156] .


               CT is the standard and first line choice for imaging studies of PACC. Visible lymph nodes were noted to be
               more frequent in PACC than PDAC. Tumor hypoattenuation in arterial phase compared to the uninvolved
               pancreas was much less frequent in PACC and PACC was much more likely to have well-defined margins
               than PDAC. Lack of bile duct dilatation was also much more common in PACC than PDAC . MRI
                                                                                                  [157]
               characteristics of PACC were investigated in a small study of 5 patients, and it was concluded that PACC
               presents as a round, encapsulated tumor with moderate and heterogeneous enhancement after gadolinium
                            [158]
               administration . Either CT or MRI can adequately detect PACC.
               Clinical manifestations of PACC
               The most common symptoms in newly diagnosed PACC patients are generally non-specific: abdominal
               pain and weight loss occur most frequently . Jaundice is an infrequent symptom even when PACC
                                                      [141]
               presents in the pancreatic head. Jaundice is very common in PDAC and PACC tumors are typically larger at
               diagnosis [141,148,159] , so the rarity of jaundice in PACC has been difficult to understand. It has been suggested
               that the more encapsulated biology of PACC is less susceptible to causing jaundice than the more infiltrative
               biology of PDAC.

               Lipase hypersecretion syndrome (LHS) is a paraneoplastic syndrome uniquely observed with PACC. Many
               PACCs produce lipase and excessive release of this enzyme into the circulation occurs in about 10%-15% of
               PACC patients, leading to accumulation of pancreatic enzymes in peripheral tissues and subsequent
               enzymatic digestion. Very elevated blood lipase levels can cause eosinophilia and panniculitis that most
               often manifests as painful subcutaneous nodules that resemble erythema nodosum. Panniculitis of LHS has
               a predilection for pressure points in the lower extremities, especially on the shins [160,161] . Another common
               feature of LHS is painful and inflammatory polyarthritis that resembles rheumatic fever or gout. It is
               thought to be secondary to periarticular fat necrosis. Joint aspirates are typically sterile but occasionally
   80   81   82   83   84   85   86   87   88   89   90